Do analysts recommend CARM or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend TPST or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tempest Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend BIVI or EVGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, BIVI or EVGN?

Evogene has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$22.07M -$3.15 N/A Evogene $3.85M 1.23 -$8.48M -$0.91 N/A

Is BIVI or EVGN more profitable?

BioVie has a net margin of 0.00% compared to Evogene's net margin of -694.18%. BioVie's return on equity of -126.02% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -126.02% -108.88% Evogene -694.18% -156.53% -86.80%

Does the media refer more to BIVI or EVGN?

In the previous week, BioVie had 6 more articles in the media than Evogene. MarketBeat recorded 8 mentions for BioVie and 2 mentions for Evogene. BioVie's average media sentiment score of 0.86 beat Evogene's score of 0.22 indicating that BioVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evogene 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend EVGN or KTTA?

Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 416.88%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Evogene. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pasithea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media prefer EVGN or KTTA?

In the previous week, Evogene had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Evogene and 1 mentions for Pasithea Therapeutics. Evogene's average media sentiment score of 0.22 beat Pasithea Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evogene 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pasithea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend EVGN or PLUR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evogene 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, EVGN or PLUR?

Evogene has higher revenue and earnings than Pluri. Evogene is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evogene $3.85M 1.23 -$8.48M -$0.91 N/A Pluri $1.34M 11.40 -$22.58M -$4.53 N/A

Is EVGN or PLUR more profitable?

Evogene has a net margin of -694.18% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Evogene's return on equity. Company Net Margins Return on Equity Return on Assets Evogene -694.18% -156.53% -86.80% Pluri -2,162.08% N/A -106.59%

Does the media prefer EVGN or PLUR?

In the previous week, Evogene had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Evogene and 1 mentions for Pluri. Pluri's average media sentiment score of 0.45 beat Evogene's score of 0.22 indicating that Pluri is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evogene 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pluri 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Evogene (EVGN) Competitors

$0.55 +0.01 (+1.04%)

As of 04:00 PM Eastern

Compare

EVGN vs. CARM, TPST, BIVI, KTTA, and PLUR

Should you buy Evogene stock or one of its competitors? Evogene's main competitors and comparable companies include Carisma Therapeutics (CARM), Tempest Therapeutics (TPST), BioVie (BIVI), Pasithea Therapeutics (KTTA), and Pluri (PLUR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Evogene compare to Carisma Therapeutics?

Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Carisma Therapeutics has a net margin of -254.28% compared to Evogene's net margin of -694.18%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	-254.28%	N/A	-192.17%
Evogene	-694.18%	-156.53%	-86.80%

Carisma Therapeutics has a beta of -9.01, meaning that its share price is 1,001% less volatile than the broader market. Comparatively, Evogene has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market.

Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carisma Therapeutics	$10.77M	0.00	-$60.48M	$0.73	0.00
Evogene	$3.85M	1.23	-$8.48M	-$0.91	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by company insiders. Comparatively, 7.4% of Evogene shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Evogene had 2 more articles in the media than Carisma Therapeutics. MarketBeat recorded 2 mentions for Evogene and 0 mentions for Carisma Therapeutics. Evogene's average media sentiment score of 0.22 beat Carisma Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Carisma Therapeutics	Neutral
Evogene	Neutral

Summary

Evogene beats Carisma Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Evogene compare to Tempest Therapeutics?

Tempest Therapeutics (NASDAQ:TPST) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

In the previous week, Evogene had 2 more articles in the media than Tempest Therapeutics. MarketBeat recorded 2 mentions for Evogene and 0 mentions for Tempest Therapeutics. Evogene's average media sentiment score of 0.22 beat Tempest Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Tempest Therapeutics	Neutral
Evogene	Neutral

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 36.2% of Tempest Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Tempest Therapeutics has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Evogene's return on equity of -156.53% beat Tempest Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tempest Therapeutics	N/A	-576.56%	-134.99%
Evogene	-694.18%	-156.53%	-86.80%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempest Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Tempest Therapeutics has a beta of -1.68, indicating that its stock price is 268% less volatile than the broader market. Comparatively, Evogene has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

Evogene has higher revenue and earnings than Tempest Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempest Therapeutics	N/A	N/A	-$26.26M	-$4.28	N/A
Evogene	$3.85M	1.23	-$8.48M	-$0.91	N/A

Summary

Evogene beats Tempest Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Evogene compare to BioVie?

BioVie (NASDAQ:BIVI) and Evogene (NASDAQ:EVGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

4.6% of BioVie shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 0.9% of BioVie shares are held by insiders. Comparatively, 7.4% of Evogene shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, BioVie had 6 more articles in the media than Evogene. MarketBeat recorded 8 mentions for BioVie and 2 mentions for Evogene. BioVie's average media sentiment score of 0.86 beat Evogene's score of 0.22 indicating that BioVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evogene	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioVie has a beta of 0.74, indicating that its share price is 26% less volatile than the broader market. Comparatively, Evogene has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

BioVie has a net margin of 0.00% compared to Evogene's net margin of -694.18%. BioVie's return on equity of -126.02% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-126.02%	-108.88%
Evogene	-694.18%	-156.53%	-86.80%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Evogene has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A
Evogene	$3.85M	1.23	-$8.48M	-$0.91	N/A

Summary

Evogene beats BioVie on 8 of the 12 factors compared between the two stocks.

How does Evogene compare to Pasithea Therapeutics?

Evogene (NASDAQ:EVGN) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

In the previous week, Evogene had 1 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 2 mentions for Evogene and 1 mentions for Pasithea Therapeutics. Evogene's average media sentiment score of 0.22 beat Pasithea Therapeutics' score of 0.00 indicating that Evogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evogene	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pasithea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pasithea Therapeutics has a net margin of 0.00% compared to Evogene's net margin of -694.18%. Pasithea Therapeutics' return on equity of -49.49% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
Pasithea Therapeutics	N/A	-49.49%	-46.81%

Pasithea Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 416.88%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Pasithea Therapeutics is more favorable than Evogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

10.4% of Evogene shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 7.4% of Evogene shares are owned by insiders. Comparatively, 1.5% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Evogene has higher revenue and earnings than Pasithea Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.23	-$8.48M	-$0.91	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$1.58	N/A

Evogene has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Summary

Pasithea Therapeutics beats Evogene on 8 of the 15 factors compared between the two stocks.

How does Evogene compare to Pluri?

Evogene (NASDAQ:EVGN) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evogene	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Evogene has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Pluri has a beta of 0.68, indicating that its stock price is 32% less volatile than the broader market.

Evogene has a net margin of -694.18% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Evogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evogene	-694.18%	-156.53%	-86.80%
Pluri	-2,162.08%	N/A	-106.59%

10.4% of Evogene shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 7.4% of Evogene shares are held by insiders. Comparatively, 43.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Evogene has higher revenue and earnings than Pluri. Evogene is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evogene	$3.85M	1.23	-$8.48M	-$0.91	N/A
Pluri	$1.34M	11.40	-$22.58M	-$4.53	N/A

In the previous week, Evogene had 1 more articles in the media than Pluri. MarketBeat recorded 2 mentions for Evogene and 1 mentions for Pluri. Pluri's average media sentiment score of 0.45 beat Evogene's score of 0.22 indicating that Pluri is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evogene	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pluri	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Evogene beats Pluri on 7 of the 13 factors compared between the two stocks.

Get Evogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EVGN vs. The Competition

Export

Metric	Evogene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.70M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.60	12.66	273.28	25.38
Price / Sales	1.23	1,309.16	613.48	92.60
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	0.83	16.29	12.89	6.14
Net Income	-$8.48M	-$22.72M	$3.47B	$349.01M
7 Day Performance	1.30%	-1.37%	-0.33%	-1.47%
1 Month Performance	1.68%	11.07%	6.51%	2.47%
1 Year Performance	-56.15%	53.71%	25.19%	15.84%

Evogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EVGN Evogene	1.1168 of 5 stars	$0.55 +1.0%	N/A	-56.1%	$4.70M	$3.85M	N/A	140
CARM Carisma Therapeutics	0.3391 of 5 stars	$0.00 -47.8%	N/A	-99.8%	$50K	$10.77M	0.00	20	Gap Down
TPST Tempest Therapeutics	0.5756 of 5 stars	$1.11 +0.9%	N/A	-89.2%	$18.19M	N/A	N/A	20	Positive News
BIVI BioVie	0.9702 of 5 stars	$2.09 -2.3%	N/A	+28.5%	$18.08M	N/A	N/A	10	Short Interest Increase
KTTA Pasithea Therapeutics	2.4688 of 5 stars	$0.56 +10.9%	$3.00 +435.7%	-35.4%	$16.87M	N/A	N/A	3	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EVGN) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evogene (EVGN) Competitors

EVGN vs. CARM, TPST, BIVI, KTTA, and PLUR

How does Evogene compare to Carisma Therapeutics?

Summary

How does Evogene compare to Tempest Therapeutics?

Summary

How does Evogene compare to BioVie?

Summary

How does Evogene compare to Pasithea Therapeutics?

Summary

How does Evogene compare to Pluri?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evogene (EVGN) Competitors

EVGN vs. CARM, TPST, BIVI, KTTA, and PLUR

How does Evogene compare to Carisma Therapeutics?

Is CARM or EVGN more profitable?

Which has more volatility & risk, CARM or EVGN?

Which has better earnings & valuation, CARM or EVGN?

Do analysts recommend CARM or EVGN?

Do institutionals and insiders believe in CARM or EVGN?

Does the media refer more to CARM or EVGN?

Summary

How does Evogene compare to Tempest Therapeutics?

Does the media refer more to TPST or EVGN?

Do insiders & institutionals hold more shares of TPST or EVGN?

Is TPST or EVGN more profitable?

Do analysts recommend TPST or EVGN?

Which has more volatility and risk, TPST or EVGN?

Which has preferable valuation and earnings, TPST or EVGN?

Summary

How does Evogene compare to BioVie?

Do insiders and institutionals believe in BIVI or EVGN?

Does the media refer more to BIVI or EVGN?

Which has more volatility & risk, BIVI or EVGN?

Is BIVI or EVGN more profitable?

Do analysts recommend BIVI or EVGN?

Which has stronger valuation and earnings, BIVI or EVGN?

Summary

How does Evogene compare to Pasithea Therapeutics?

Does the media prefer EVGN or KTTA?

Is EVGN or KTTA more profitable?

Do analysts recommend EVGN or KTTA?

Do institutionals and insiders hold more shares of EVGN or KTTA?

Which has higher valuation and earnings, EVGN or KTTA?

Which has more volatility and risk, EVGN or KTTA?

Summary

How does Evogene compare to Pluri?

Do analysts recommend EVGN or PLUR?

Which has more volatility & risk, EVGN or PLUR?

Is EVGN or PLUR more profitable?

Do institutionals & insiders believe in EVGN or PLUR?

Which has stronger earnings and valuation, EVGN or PLUR?

Does the media prefer EVGN or PLUR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVGN vs. The Competition

Evogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools